Phase I Study of Preventive HIV Vaccine Shows Improved Immune Responses When the Vaccine is Delivered by Electrical Impulses
Printable version A Phase 1 study of a preventive HIV vaccine show that a novel delivery mechanism known as electroporation helped to enhance the immunogenicity of the vaccine tested. Results were presented at the end of October at the AIDS Vaccine Conference in Paris, France. Please see the IAVI and Ichor Medical Systems, Inc. announcement below for more information.
